PML with dimethyl fumarate—No convincing case against natalizumab

Abstract

Get full access to this article

View all access options for this article.

References

Diebold

Altersberger

Decard

et al. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler 2019; 25: 1682–1685.

Marshall

Ferenczy

Daley

et al. Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J Virol 2014; 88(9): 5177–5183.

Meira

Sievers

Hoffmann

et al. Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development. Neurol Neuroimmunol Neuroinflamm 2016; 3(3): e223.

Derfuss

Kovarik

Kappos

et al. alpha4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurol Neuroimmunol Neuroinflamm 2017; 4(5): e388.

Fine

Sorbello

Kortepeter

et al. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2014; 75: 108–115.

Gieselbach

Muller-Hansma

Wijburg

et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 2017; 264: 1155–1164.